myeloproliferative neoplasms (MPN) | Page 6 | Aplastic Anemia & MDS International Foundation

myeloproliferative neoplasms (MPN)

Aaron Gerds, MD, MS

Gerds, Aaron
The Cleveland Clinic Taussig Cancer Institute

Dr. Aaron Gerds completed his undergraduate degree with honors (B.A. in biology and chemistry) at Hope College in Holland, Michigan. He then obtained his M.D. from Loyola University Chicago Stritch School of Medicine. Dr. Gerds stayed at Loyola University Hospital for his Internal Medicine residency training where he also served as chief resident. This is when he first became interested in hematology while analyzing the results of clinical trials under the mentorship of Dr. Patrick Stiff.

Corey Cutler, MD, MPH, FRCPC

Cutler, Corey
Dana-Farber Cancer Institute

Dr. Cutler received his MD from McGill University, Montreal, Canada. He subsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff.

Andrew Brunner, MD

Brunner, Andrew
Massachusetts General Hospital

Dr. Brunner's clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given